<DOC>
	<DOC>NCT02891681</DOC>
	<brief_summary>To determine the accuracy of NIR/US assessment of tumor vasculature and oxygen changes in predicting and monitoring early neoadjuvant treatment response compared to pathological response.</brief_summary>
	<brief_title>Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Scheduled to receive neoadjuvant chemotherapy for the treatment of newly diagnosed, locally advanced breast cancer or scheduled to receive neoadjuvant endocrine therapy with the eventual goal of surgery of newly diagnosed clinical stage IIIII ER+ HER2 breast cancer (for the endocrine therapy cohort) At least 18 years of age Female Able to understand and willing to sign an IRBapproved written informed consent document Pregnant and/or breastfeeding Prior history of breast cancer Prior history of chest wall radiation Prior history of breast reconstruction, reduction, or augmentation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>